{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:34:11Z","timestamp":1787222051230,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.urology.2023.11.021","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T16:14:15Z","timestamp":1702138455000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5823-0624","authenticated-orcid":false,"given":"Max","family":"Bowman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille A.","family":"V\u00e9lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Jericevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Mbassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Van Kuiken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.11.021_bib1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2009.03.080","article-title":"Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland","volume":"57","author":"Tikkinen","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.021_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","article-title":"Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey","volume":"57","author":"Liberman","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.021_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2023.11.021_bib4","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"issue":"5, Supplement 2","key":"10.1016\/j.urology.2023.11.021_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.urology.2003.09.008","article-title":"Diagnosis and treatment of the overactive bladder","volume":"62","author":"Wein","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.021_bib6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2009.09036.x","article-title":"Patient-reported reasons for discontinuing overactive bladder medication","volume":"105","author":"Benner","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.11.021_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urpr.2015.06.011","article-title":"AUA white paper on the beers criteria for potentially inappropriate medication use in older adults","volume":"3","author":"Griebling","year":"2016","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2023.11.021_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/SPV.0000000000001008","article-title":"Clinical Consensus Statement: association of anticholinergic medication use and cognition in women with overactive bladder","volume":"27","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2023.11.021_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/SPV.0000000000001190","article-title":"Adverse events for overactive bladder medications from a public federal database","volume":"28","author":"Sze","year":"2022","journal-title":"Urogynecology"},{"key":"10.1016\/j.urology.2023.11.021_bib10","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.urology.2023.11.021_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2023.11.021_bib12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","article-title":"Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults","volume":"73","author":"Risacher","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.urology.2023.11.021_bib13","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2023.11.021_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/archinternmed.2009.229","article-title":"Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study","volume":"169","author":"Carri\u00e8re","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.urology.2023.11.021_bib15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1S","key":"10.1016\/j.urology.2023.11.021_bib16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/SPV.0000000000001272","article-title":"Overactive bladder and cognitive impairment: the American Urogynecologic Society and pelvic floor disorders research foundation state-of-the-science conference summary report","volume":"29","author":"Dengler","year":"2023","journal-title":"Urogynecology"},{"key":"10.1016\/j.urology.2023.11.021_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European\u2013Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.021_bib18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.021_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1185\/03007995.2016.1149806","article-title":"Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics","volume":"32","author":"Wagg","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.urology.2023.11.021_bib20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.11.021_bib21","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/nau.25040","article-title":"Mirabegron and antimuscarinic use in frail overactive bladder patients in the United States Medicare population","volume":"41","author":"Johnson","year":"2022","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2023.11.021_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.urpr.2016.03.009","article-title":"The AUA Quality Registry: engaging stakeholders to improve the quality of care for patients with prostate cancer","volume":"4","author":"Cooperberg","year":"2017","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2023.11.021_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.urology.2020.04.109","article-title":"Racial and socioeconomic factors influence utilization of advanced therapies in commercially insured OAB patients: an analysis of over 800,000 OAB patients","volume":"142","author":"Syan","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.021_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.urology.2022.11.006","article-title":"National trends in third-line treatment for overactive bladder among commercially insured women, 2010-2019","volume":"175","author":"Edge","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.021_bib25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2009.12.025","article-title":"A comparison of the frequencies of medical therapies for overactive bladder in men and women: analysis of more than 7.2 million aging patients","volume":"57","author":"Helfand","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.11.021_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/AOG.0000000000004279","article-title":"Rethinking second-line therapy for overactive bladder to improve patient access to treatment options","volume":"137","author":"Escobar","year":"2021","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.urology.2023.11.021_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.urology.2018.12.021","article-title":"Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population","volume":"126","author":"Mckellar","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.11.021_bib28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/UPJ.0000000000000243","article-title":"Yearly trends of overactive bladder medication usage","volume":"8","author":"Chua","year":"2021","journal-title":"Urol Pract"},{"key":"10.1016\/j.urology.2023.11.021_bib29","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1001\/jama.2020.11413","article-title":"Trends in industry payments to physicians in the United States from 2014 to 2018","volume":"324","author":"Marshall","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2023.11.021_bib30","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.urology.2018.04.008","article-title":"The receipt of industry payments is associated with prescribing promoted alpha-blockers and overactive bladder medications","volume":"117","author":"Modi","year":"2018","journal-title":"Urology"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042952301052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009042952301052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T23:42:47Z","timestamp":1709682167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009042952301052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"alternative-id":["S009042952301052X"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.021","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors Influencing Medication Selection for Management of Overactive Bladder: Trends and Insights From AUA Quality Registry","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}